Filip Callewaert

Gent, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.

Journal: Muscle & nerve

Published: January 24, 2025

Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.

Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.

Journal: Vox sanguinis

Published: October 21, 2024

Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.

Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 29, 2022

Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Journal: Journal of clinical pharmacology

Published: July 07, 2021

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

Journal: Blood advances

Published: March 09, 2020

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 30, 2019

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply.

Journal: The New England journal of medicine

Published: May 03, 2019

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.

Journal: Expert review of clinical pharmacology

Published: April 13, 2019

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Journal: The New England journal of medicine

Published: January 10, 2019

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 24, 2017

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Journal: The New England journal of medicine

Published: June 23, 2016

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Journal: The New England journal of medicine

Published: February 11, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026